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Abstract
The treatment of Paget’s disease of bone (PDB) aims at the suppression of abnormal bone turnover; bisphosphonates are currently the 
treatment of choice. Indications for antiresorptive treatment in symptomatic patients with PDB include bone or joint pain, neurological 
complications, surgery planned at an active pagetic site and hypercalcaemia from immobilisation. The goals of antiresorptive treatment 
are clinical improvement and biochemical remission, as assessed by the normalisation of bone turnover markers. Clinical deterioration, 
especially bone pain, should be considered before deciding to treat patients with late sclerotic (‘burned-out’) PDB. Bone scintigraphy may 
be of importance in these patients, because it depicts increased osteoblastic activity, when bone markers may not. We present a case of 
late sclerotic PDB with clinical deterioration but normal bone turnover markers, who experienced significant clinical improvement after 
treatment with zoledronic acid. (Endokrynol Pol 2012; 63 (4): 312–315)
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Streszczenie
Celem leczenia choroby kości Pageta (PDB) jest zahamowanie zwiększonego obrotu kostnego. Obecnie lekami z wyboru są bisfosfoniany. 
Do wskazań do stosowania leków antyresorpcyjnych u pacjentów z objawowa postacią PDB należą: bóle kostne i stawowe, powikłania 
neurologiczne, planowany zabieg chirurgiczny w rejonie aktywnych zmian chorobowych i hiperkalcemia spowodowana unierucho-
mieniem. Celem terapii antyresorpcyjnej jest uzyskanie poprawy stanu klinicznego i remisji biochemicznej, ocenianej na podstawie 
normalizacji stężeń biomarkerów obrotu kostnego. Przed podjęciem decyzji o wdrożeniu terapii u chorych w późnej, sklerotycznej fazie 
choroby (burned out) należy wziąć pod uwagę pogorszenie stanu klinicznego, a zwłaszcza występowanie bólów kostnych. U tych chorych 
duże znaczenie ma badanie scyntygraficzne kości, ponieważ może ono uwidocznić zwiększoną aktywność osteoblastyczną, której mogą 
nie wykazać markery obrotu kostnego. W niniejszej pracy przedstawiono przypadek chorego w późnym, sklerotycznym stadium PDB, 
u którego występowały nasilone objawy kliniczne, lecz stężenia markerów obrotu kostnego były prawidłowe. Po leczeniu kwasem zole-
dronowym nastąpiła istotna poprawa kliniczna. (Endokrynol Pol 2012; 63 (4): 312–315)
Słowa kluczowe: bisfosfoniany, scyntygrafia kości, izoenzym kostny fosfatazy alkalicznej, C-końcowy telopeptyd kolagenu typu I, choroba Pageta 
kości, kwas zoledronowy
Introduction
Paget’s disease of bone (PDB) is the second common-
est metabolic bone disease, after osteoporosis. PDB is 
a chronic disorder characterised by focally high bone 
remodelling, with abnormalities in all the phases of the 
remodelling cycle, although the primary abnormality 
is believed to lie in the regulation of osteoclasts, which 
are increased in both number and size [1–3]. The treat-
ment of PDB aims at the suppression of abnormal bone 
turnover, and bisphosphonates (BPs) are currently the 
treatment of choice [1, 4, 5]. Zoledronic acid (ZOL) leads 
to quicker and more sustained therapeutic response 
compared to other BPs such as risedronate [6, 7] or 
313
Endokrynologia Polska/Polish Journal of Endocrinology 2012; 63 (4)
O
PI
S 
PR
Z
Y
PA
D
K
U
pamidronate [8]. Besides clinical improvement and bio-
chemical remission, a favourable scintigraphic response 
evident as early as three months after treatment with 
ZOL has been reported in patients with PDB [9].
Indications for antiresorptive treatment in symp-
tomatic patients with PDB include bone or joint pain, 
neurological complications, surgery planned at an active 
pagetic site and hypercalcaemia from immobilisation 
[4, 5]. The goals of antiresorptive treatment are clinical 
improvement and biochemical remission, as assessed by 
the normalisation of bone turnover markers [10]. The 
increased levels of bone markers are generally believed 
to reflect the rate of bone remodelling and correlate 
directly with the extent of the skeletal involvement 
[11]. Total serum alkaline phosphatase (ALP) is the most 
used marker in clinical practice, because it reflects the 
disease activity and treatment efficacy and, additionally, 
it is cheap, widely available, and has a low inter-assay 
variability [4].
We hereby present a case of late sclerotic (‘burned-out’) 
PDB with clinical deterioration but normal bone 
turnover markers, who experienced significant clinical 
improvement after treatment with ZOL.
Case description
A Caucasian woman, born in 1923, was diagnosed with 
symptomatic polyostotic PDB in 1980, (ALP 501, nor-
mal range 30–130 IU/L). She initially received courses 
of calcitonin for 16 years (until 1996) with only partial 
decreases in bone pain and ALP. Subsequently, when 
ALP was increased, she had been receiving courses of 
alendronate (1997 and 2001) and risedronate (2003 and 
2005) treatment, which led to transient biochemical 
and clinical remissions. The last course of risedronate 
treatment was completed in March 2005. Since then, 
the patient experienced progressively deteriorating 
bone and articular pain, rendering her unable to walk 
without the help of a stick from March 2006. Because of 
clinical deterioration and the suspicion of malignancy, 
she was subjected to bone scintigraphy (September 
2006), which confirmed polyostotic PDB with enhanced 
tracer uptake mainly in the skull, pelvis and spine, and 
diffuse degenerative articular lesions (Figure 1A). Char-
acteristically, plain radiographs were suggestive of late 
sclerotic PDB (Figure 1B). Given that the low patient’s 
ALP (129 IU/L) was incompatible with clinical deteriora-
tion, serum bone-specific alkaline phosphatase (BALP) 
and C-terminal cross-linking telopeptide of type I col-
lagen (CTX) were measured by established methods, 
as elsewhere reported [12]; however, they were also 
within normal range (BALP: 39.4 IU/L, normal range 
14–43 IU/L; CTX: 0.66 ng/mL, normal range 0.12– 
–0.75 ng/mL). Serum calcium, phosphate, albumin, parathy-
roid hormone, and kidney and liver function tests were 
within normal range.
In an attempt to deal with her clinical deteriora-
tion, the patient was administered a single 5 mg ZOL 
infusion (October 2006), after a 10-day administration 
of calcium and cholecalciferol supplements, as previo- 
usly reported [9]. She did not experience an acute 
phase reaction. She reported bone and articular pain 
improvement, which started ten days after ZOL and 
sustained for approximately 12 months. Notably, 
she was able to walk without a stick from November 
2006. As it has been elsewhere defined [4, 10], the 
patient had an acceptable (> 25–30% decrease in 
ALP) biochemical response to treatment at 6 months, 
being a 33% decrease in ALP and a 36% decrease in 
BALP, which lasted for at least 12 months and tended 
to relapse at 18 months after ZOL (ALP: 86 IU/L at 
6 months, 85 IU/L at 12 months, 113 IU/L at 18 months; 
BALP: 25.2 IU/L, 27.9 IU/L, 44.5 IU/L, respectively). 
However, serum CTX remained essentially un-
changed (0.75 ng/mL, 0.66 ng/mL and 0.63 ng/mL, 
respectively). The patient deceased from sudden 
cardiac arrest in September 2008, being 85 years old.
Discussion
A woman with symptomatic, late sclerotic, polyostotic 
PDB, who experienced significant clinical improvement 
after treatment with ZOL, despite normal bone turnover 
markers, is hereby presented.
There are limited similar cases in the literature. Ang 
et al. described three patients with symptomatic active 
PDB and normal ALP levels [13]. All three patients 
had radiographic findings of PDB, increased uptake 
of radiotracer on bone scintigraphy, but normal ALP; 
however, they all had elevated levels of urinary mark-
ers of bone resorption. The patients were administered 
pamidronate intravenously (60 mg once weekly for 
2–3 consecutive weeks), after which bone pain and 
scintigraphy were improved, urinary markers of bone 
resorption were normalised, and ALP was decreased by 
19–36% [13], approximately as in our case.
Gkouva et al. described a patient with symptomatic 
monostotic PDB, but normal ALP and urinary hydroxy-
proline [14]. She had been treated for osteoporosis with 
alendronate for the previous four years, which could 
partly account for normal bone markers. Furthermore, 
she had repeatedly received anti-inflammatory medi-
cation for tibia pain without significant relief. PDB was 
confirmed by tibia plain radiograph, bone scintigraphy 
and biopsy of the lesion. She was administered ZOL 
intravenously (5 mg once), resulting in improvement 
of bone pain and scintigraphy and a 45% decrease of 
ALP [14].
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Figure 1A. Bone scintigraphy showing polyostotic Paget’s disease of bone with enhanced tracer uptake more prominently on skull, 
pelvis and spine, and dispersed degenerative articular lesions before zoledronic acid infusion; B. Radiograph of the skull showing 
a ‘cotton-wool’ appearance indicative of the sclerotic phase of Paget’s disease of bone
Rycina 1A. Scyntygrafia kości przed podaniem we wlewie kwasu zoledronowego: cechy poliostotycznej choroby Pageta ze zwiększonym 
wychwytem znacznika, zwłaszcza w kościach czaszki, miednicy i kręgosłupa, oraz rozsiane degeneracyjne zmiany stawowe; B. RTG 
czaszki: zmiany typu „kłębków waty” sugerujące sklerotyczną fazę choroby kości Pageta
A
B
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Unlike the Ang et al. cases [13], in our and Gkouva’s 
patients [14], all measured markers were within normal 
ranges. However, more sensitive bone formation and 
resorption markers (BALP and CTX) were measured in 
our case, which, in accordance to ALP, confirmed the 
disease’s biochemical inactivity. Unlike the Gkouva case, 
our patient had a long-established diagnosis of PDB, 
which is consistent with her late sclerotic phase of PDB. 
The decision for treatment was based on clinical and 
scintigraphic criteria in all the above cases; the subse-
quent clinical and biochemical improvement supports 
the necessity of treatment in these patients.
Although ALP is the bone marker of choice for the 
diagnosis and follow-up of PDB patients [1, 4], BALP 
is considered to be the most sensitive marker in the 
evaluation of monostotic disease or in a case of limited 
bone involvement, as it can be increased in up to 60% of 
patients with normal ALP [1, 15]. However, even BALP 
can be normal in very limited bone involvement [11]. 
ALP and BALP levels result from the increased number 
of osteoblasts in the pagetic lesions. Their increased 
levels reflect the rate of bone formation and correlate 
directly with the extent of skeletal involvement [11]. 
During the natural course of PDB, ALP activity may 
increase for many years, reflecting both expansion of 
disease through affected bones and increased metabolic 
activity [2]. After reaching its maximal extent and activ-
ity, the disease remains more or less stable for many 
years, with relatively small fluctuations in ALP levels [2].
In accordance with this observation, it seems that 
even the most sensitive markers, including BALP and 
CTX, can be within normal ranges when PDB progresses 
in the ‘burned-out’ phase, despite clinical deterioration. 
Furthermore, given the unexpectedly distinct response 
to ZOL of bone formation compared to bone resorption 
markers, we speculate that CTX may not be a sensitive 
marker for osteoclastic activity in cases of ‘burned-out’ 
PDB. The acceptable decrease in ALP, whose methods 
are better standardised than CTX, is directly indicative of 
a decrease in osteoblastic activity, and indirectly indicative 
of both a decrease in osteoclastic activity and integrity 
of the coupling mechanism (between osteoclastic and 
osteoblastic activity) in our patient. The clinical improve-
ment of our patient could be attributed to this response to 
treatment, but also to a possible effect of ZOL on cartilage, 
given that ZOL has been reported to decrease CTX-II, 
thereby diminishing cartilage collagen degradation [16].
In conclusion, active PDB may be present not only 
with normal ALP levels, but also with normal BALP 
and CTX. Clinical deterioration, especially bone pain, 
should be considered before deciding to treat patients 
with late sclerotic PDB. Bone scintigraphy may be 
of importance in these patients, because it depicts 
increased osteoblastic activity, when bone markers 
may not. BPs treatment in these patients can lead to 
clinical improvement.
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